Growing interest of DPP4 inhibitors as an anti-diabetic therapeutic owing to its cardio-protective effects (7) has led to the investigation of its plasma activity, plasma concentrations and its association with glycemic deregulation in T2DM by multiple groups. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.